• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by MaxCyte Inc. (Amendment)

    2/14/23 10:15:37 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $MXCT alert in real time by email
    SC 13G/A 1 doc1.htm NONE Schedule 13G


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 01)*
     
    MaxCyte, Inc. 

    (Name of Issuer)
     
    Common Stock

    (Title of Class of Securities)
     
    57777K106

    (CUSIP Number)
     
    Calendar Year 2022

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         x  Rule 13d-1(b)
     
         o  Rule 13d-1(c)
     
         o  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  57777K106      
     
          
    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     BAMCO INC /NY/
    000000000
       
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a)   o
     (b)   x
       
    3 SEC USE ONLY
      
      
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
      
     New York
        
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER
      
     0
       
    6 SHARED VOTING POWER
      
     2,182,982
       
    7 SOLE DISPOSITIVE POWER
      
     0
       
    8 SHARED DISPOSITIVE POWER
      
     2,182,982
       
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     2,182,982
       
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     o
       
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     2.14%
       
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     IA ,  CO
     

    FOOTNOTES
      
     
     
     

     
     
    CUSIP No.  57777K106      
     
          
    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     Baron Capital Management, Inc.
    000000000
       
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a)   o
     (b)   x
       
    3 SEC USE ONLY
      
      
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
      
     New York
        
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER
      
     0
       
    6 SHARED VOTING POWER
      
     0
       
    7 SOLE DISPOSITIVE POWER
      
     0
       
    8 SHARED DISPOSITIVE POWER
      
     0
       
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     0
       
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     o
       
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     0%
       
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     IA ,  CO
     

    FOOTNOTES
      
     
     
     

     
     
    CUSIP No.  57777K106      
     
          
    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     Ronald Baron
    000000000
       
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a)   o
     (b)   x
       
    3 SEC USE ONLY
      
      
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
      
     New York
        
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER
      
     0
       
    6 SHARED VOTING POWER
      
     2,182,982
       
    7 SOLE DISPOSITIVE POWER
      
     0
       
    8 SHARED DISPOSITIVE POWER
      
     2,182,982
       
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     2,182,982
       
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     o
       
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     2.14%
       
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     HC ,  IN
     

    FOOTNOTES
      
     
     
     

     
     
    CUSIP No.  57777K106      
     
          
    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     Baron Capital Group, Inc.
    000000000
       
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a)   o
     (b)   x
       
    3 SEC USE ONLY
      
      
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
      
     New York
        
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER
      
     0
       
    6 SHARED VOTING POWER
      
     2,182,982
       
    7 SOLE DISPOSITIVE POWER
      
     0
       
    8 SHARED DISPOSITIVE POWER
      
     2,182,982
       
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     2,182,982
       
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     o
       
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     2.14%
       
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     HC ,  CO
     

    FOOTNOTES
      
     
     
     

     
     
    Item 1.

     
    (a)
    Name of Issuer
     
     
    MaxCyte, Inc.

     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    22 FIRSTFIELD ROAD, SUITE 250, GAITHERSBURG, MD, 20878

    Item 2.

     
    (a)
    Name of Person Filing
     
     
    Baron Capital Group, Inc. ("BCG")
    BAMCO, Inc. ("BAMCO")
    Baron Capital Management, Inc. ("BCM")
    Ronald Baron

     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    767 FIFTH AVENUE
    49TH FLOOR

     
    (c)
    Citizenship
     
     
    New York

     
    (d)
    Title of Class of Securities
     
     
    Common Stock

     
    (e)
    CUSIP Number
     
     
    57777K106

     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     
    (e)
    x
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     
    (g)
    x
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).

     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     
    (a)
    Amount beneficially owned: 2,182,982

     
    (b)
    Percent of class: 2.14%

     
    (c)
    Number of shares as to which the person has:

     
    (i)
    Sole power to vote or to direct the vote: 0

     
    (ii)
    Shared power to vote or to direct the vote: 2,182,982

     
    (iii)
    Sole power to dispose or to direct the disposition of: 0

     
    (iv)
    Shared power to dispose or to direct the disposition of: 2,182,982

    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x .
     
    Filing persons have ceased being the beneficial owners of more than 5% of the filing class of securities reported herein.
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    The advisory clients of BAMCO and BCM have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Issuer's common stock in their accounts.
    To the best of the Filing Persons' knowledge, no such person has such interest relating to more than 5% of the outstanding class of securities.
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    BAMCO and BCM are subsidiaries of BCG. Ronald Baron owns a controlling interest in BCG.
     
    Item 8.
    Identification and Classification of Members of the Group
     
    Please see item 3.
     
    Item 9.
    Notice of Dissolution of Group
     
    n/a
     
     
     

     
     
     
    Item 10.
    Certification
      
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
     BAMCO, Inc.
     
        
    Date: February 14, 2023
    By:
    /s/  Ronald Baron 
       Name: Ronald Baron 
       Title:  Chairman and CEO  
        
     
     
     
     Baron Capital Group, Inc.
     
        
    Date: February 14, 2023
    By:
    /s/  Ronald Baron 
       Name: Ronald Baron 
       Title:  Chairman and CEO  
        
     
     
     
     Baron Capital Management, Inc.
     
        
    Date: February 14, 2023
    By:
    /s/  Ronald Baron 
       Name: Ronald Baron 
       Title:  Chairman and CEO  
        
     
     
     
     Ronald Baron
     
        
    Date: February 14, 2023
    By:
    /s/  Ronald Baron 
       Name: Ronald Baron 
       Title:  Individually  
        
     
    Footnotes:

    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     


    Get the next $MXCT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MXCT

    DatePrice TargetRatingAnalyst
    11/29/2023$7.00Buy
    Craig Hallum
    10/15/2021Outperform
    Cowen
    8/24/2021$36.00Outperform
    Wedbush
    8/24/2021Outperform
    William Blair
    8/24/2021$19.00Overweight
    Stephens
    8/24/2021Outperform
    Cowen & Co.
    8/24/2021$18.00Buy
    Stifel
    8/24/2021$22.00Buy
    BTIG
    More analyst ratings

    $MXCT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

      ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2025 financial results and reiterated its 2025 guidance. First Quarter and Recent Highlights Core business revenue of $8.2 million in the first quarter of 2025, an increase of 1% over the first quarter of 2024.Strategic Platform License (SPL) Program-related revenue was $2.1 million for the first quarter of 2025, compared to $3.2 million in the first quarter of

      5/7/25 4:05:00 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

      ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2025 after the U.S. market close on Wednesday, May 7th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance.

      4/10/25 2:00:00 AM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

      ROCKVILLE, Md., March 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its fourth quarter and full year ended December 31, 2024 financial results and initiated its 2025 guidance. Fourth Quarter and Full Year Highlights Total revenue of $8.7 million in the fourth quarter of 2024, a decrease of 45% over the fourth quarter of 2023. The decrease in total revenue was due to multiple one-time approval milestones in the fourth quarter of 2023.Core business revenue of $8.6 m

      3/11/25 4:05:00 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MXCT
    Leadership Updates

    Live Leadership Updates

    See more
    • MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

      ROCKVILLE, Md., Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the completion of an internal operational review, initiated earlier this year following the appointment of Maher Masoud as President and Chief Executive Officer. This "bottom-up" review focused on optimizing new product development, manufacturing, commercial execution, and capital allocation to enhance efficiency and align resources with strategic priorities. As part of an effort to streamline operations,

      12/9/24 2:00:00 AM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • MaxCyte Appoints Cynthia Collins to its Board of Directors

      ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Mahe

      10/15/24 8:05:00 AM ET
      $CERT
      $MXCT
      $PSTX
      Computer Software: Prepackaged Software
      Technology
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

      ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024. In his new role, Mr. Soleymannezhad will lead MaxCyte's commercial operations to increase adoption of the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to customers, and expand the Company's market impact in Cell and

      10/10/24 8:05:00 AM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MXCT
    Financials

    Live finance-specific insights

    See more
    • MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

      ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2025 financial results and reiterated its 2025 guidance. First Quarter and Recent Highlights Core business revenue of $8.2 million in the first quarter of 2025, an increase of 1% over the first quarter of 2024.Strategic Platform License (SPL) Program-related revenue was $2.1 million for the first quarter of 2025, compared to $3.2 million in the first quarter of

      5/7/25 4:05:00 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

      ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2025 after the U.S. market close on Wednesday, May 7th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance.

      4/10/25 2:00:00 AM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

      ROCKVILLE, Md., March 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its fourth quarter and full year ended December 31, 2024 financial results and initiated its 2025 guidance. Fourth Quarter and Full Year Highlights Total revenue of $8.7 million in the fourth quarter of 2024, a decrease of 45% over the fourth quarter of 2023. The decrease in total revenue was due to multiple one-time approval milestones in the fourth quarter of 2023.Core business revenue of $8.6 m

      3/11/25 4:05:00 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MXCT
    SEC Filings

    See more
    • SEC Form 10-Q filed by MaxCyte Inc.

      10-Q - MAXCYTE, INC. (0001287098) (Filer)

      5/8/25 5:04:27 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • MaxCyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - MAXCYTE, INC. (0001287098) (Filer)

      5/7/25 4:14:32 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form DEF 14A filed by MaxCyte Inc.

      DEF 14A - MAXCYTE, INC. (0001287098) (Filer)

      4/28/25 4:58:55 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MXCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Soleymannezhad Ali sold $3,850 worth of shares (1,211 units at $3.18), decreasing direct ownership by 2% to 59,439 units (SEC Form 4)

      4 - MAXCYTE, INC. (0001287098) (Issuer)

      3/20/25 6:49:14 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • GENERAL COUNSEL Sandoval David I. sold $1,122 worth of shares (353 units at $3.18), decreasing direct ownership by 0.55% to 64,219 units (SEC Form 4)

      4 - MAXCYTE, INC. (0001287098) (Issuer)

      3/20/25 6:47:50 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • CHIEF FINANCIAL OFFICER Swirsky Douglas J sold $22,061 worth of shares (6,939 units at $3.18), decreasing direct ownership by 6% to 111,811 units (SEC Form 4)

      4 - MAXCYTE, INC. (0001287098) (Issuer)

      3/20/25 6:08:37 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MXCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on MaxCyte with a new price target

      Craig Hallum initiated coverage of MaxCyte with a rating of Buy and set a new price target of $7.00

      11/29/23 7:39:04 AM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Cowen resumed coverage on MaxCyte

      Cowen resumed coverage of MaxCyte with a rating of Outperform

      10/15/21 8:51:03 AM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Wedbush initiated coverage on MaxCyte with a new price target

      Wedbush initiated coverage of MaxCyte with a rating of Outperform and set a new price target of $36.00

      8/24/21 7:53:48 AM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MXCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Masoud Maher bought $489,066 worth of shares (100,000 units at $4.89) (SEC Form 4)

      4 - MAXCYTE, INC. (0001287098) (Issuer)

      6/10/24 5:55:54 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MXCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by MaxCyte Inc.

      SC 13G/A - MAXCYTE, INC. (0001287098) (Subject)

      11/13/24 7:14:35 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13G/A filed by MaxCyte Inc.

      SC 13G/A - MAXCYTE, INC. (0001287098) (Subject)

      10/31/24 4:23:48 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed by MaxCyte Inc.

      SC 13G - MAXCYTE, INC. (0001287098) (Subject)

      3/25/24 4:36:08 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care